FDA approves first dual-indication anxiety drug for dogs

The FDA on May 6, 2026, approved Tessie (tasipimidine oral solution) as the first drug labeled for both noise aversion and separation anxiety in dogs, giving veterinarians a single prescription option for two fear-based conditions that often overlap. The product is an oral alpha-2 adrenoceptor agonist sponsored by Orion Corporation, and it’s meant to be given about one hour before an anticipated noise trigger or before a dog is left alone. According to the FDA’s approval materials, Tessie can be dosed up to three times in 24 hours with at least three hours between doses, and the most commonly reported adverse reactions were vomiting, lethargy, and, in separation-anxiety studies, diarrhea. (fda.gov)

Why it matters: For veterinary professionals, the approval is notable less because it introduces an entirely new behavioral concept, and more because it formalizes a labeled option for comorbid cases that can be difficult to manage in practice. FDA reviewers said effectiveness for noise aversion was supported by a field study in 160 client-owned dogs, while separation-anxiety effectiveness was supported by an 8-week field study in 224 client-owned dogs. That matters in a category where clinicians often have to combine behavior modification with off-label or condition-specific medication choices. Veterinary behaviorist Christopher Pachel has also emphasized that untreated panic can interfere with progress, and that comorbid diagnoses, including noise-related fear, should be identified early when building treatment plans. (animaldrugsatfda.fda.gov)

What to watch: Watch for how quickly general practitioners adopt Tessie in comorbid anxiety cases, and whether post-launch use clarifies where situational dosing fits best versus longer-term maintenance medication. (animaldrugsatfda.fda.gov)